On Monday, Dexcom Inc (NASDAQ: DXCM) was -1.16% down from the session before settling in for the closing price of $136.14. A 52-week range for DXCM has been $74.75 – $142.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 28.80% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 15.91%. With a float of $377.37 million, this company’s outstanding shares have now reached $385.40 million.
In an organization with 9600 employees, it is important to assess its efficiency.
Dexcom Inc (DXCM) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Dexcom Inc stocks. The insider ownership of Dexcom Inc is 2.11%, while institutional ownership is 99.00%. The most recent insider transaction that took place on Apr 08 ’24, was worth 6,864,136. In this transaction President CEO and Chairman of this company sold 49,633 shares at a rate of $138.30, taking the stock ownership to the 283,893 shares. Before that another transaction happened on Mar 28 ’24, when Company’s EVP Chief Legal Officer sold 2,624 for $140.04, making the entire transaction worth $367,472. This insider now owns 68,682 shares in total.
Dexcom Inc (DXCM) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 15.91% per share during the next fiscal year.
Dexcom Inc (NASDAQ: DXCM) Trading Performance Indicators
You can see what Dexcom Inc (DXCM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.32. Likewise, its price to free cash flow for the trailing twelve months is 101.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.31, a number that is poised to hit 0.27 in the next quarter and is forecasted to reach 2.24 in one year’s time.
Technical Analysis of Dexcom Inc (DXCM)
Let’s dig in a bit further. During the last 5-days, its volume was 2.33 million. That was inferior than the volume of 2.99 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 49.11%. Additionally, its Average True Range was 4.10.
During the past 100 days, Dexcom Inc’s (DXCM) raw stochastic average was set at 80.39%, which indicates a significant increase from 27.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.52% in the past 14 days, which was lower than the 33.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $128.55, while its 200-day Moving Average is $114.89. However, in the short run, Dexcom Inc’s stock first resistance to watch stands at $136.88. Second resistance stands at $139.21. The third major resistance level sits at $140.40. If the price goes on to break the first support level at $133.37, it is likely to go to the next support level at $132.18. The third support level lies at $129.85 if the price breaches the second support level.
Dexcom Inc (NASDAQ: DXCM) Key Stats
There are 385,515K outstanding shares of the company, which has a market capitalization of 51.87 billion. As of now, sales total 3,622 M while income totals 541,500 K. Its latest quarter income was 1,035 M while its last quarter net income were 256,300 K.
